Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.33 |
| ▸ | XDH | P47989 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653287 | 0.79 | KMT2A (0.41) | CDC7DBF4POLB | |
| SCHEMBL2034194 | 0.75 | TLR8 (0.44) | CDC7DBF4HRH4ROCK1HRH3 | |
| SCHEMBL3604391 | 0.72 | HRH4 (0.39) | HRH4ROCK1HRH3NUDT1GSK3A | |
| SCHEMBL4567243 | 0.70 | KMT2A (0.43) | CDC7DBF4XDHPOLB | |
| Bromide SCHEMBL4518423 | 0.70 | HRH4 (0.38) | CDC7DBF4HRH4ROCK1HRH3 | |
| SCHEMBL11257832 | 0.69 | CYP1A2 (0.44) | — | |
| SCHEMBL882674 | 0.69 | ALDH1A1 (0.45) | CDC7DBF4HRH4CCNE1CDK2 | |
| SCHEMBL30086177 | 0.68 | POLB (0.39) | CDC7DBF4HRH4CCNE1CDK2 | |
| SCHEMBL1457909 | 0.67 | KDM4E (0.58) | HRH4ROCK1 | |
| SCHEMBL2606614 | 0.67 | ROCK1 (0.49) | CDC7DBF4HRH4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426417-B2 | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-04-23 | — | — | US | disclosed |
| US-20120122882-A1 | Substituted Pyrrolo-Pyrimidine Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122882-A1 | Substituted Pyrrolo-Pyrimidine Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | DCK, MAP3K19, MAP3K5 | CDC7 311/4885DBF4 2065/4885HRH4 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.